Form 8-K - Current report:
SEC Accession No. 0001737287-23-000056
Filing Date
2023-06-07
Accepted
2023-06-07 16:16:32
Documents
12
Period of Report
2023-06-03
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K allo-20230603.htm   iXBRL 8-K 53463
  Complete submission text file 0001737287-23-000056.txt   193203

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20230603.xsd EX-101.SCH 1989
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20230603_lab.xml EX-101.LAB 24139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20230603_pre.xml EX-101.PRE 12595
6 EXTRACTED XBRL INSTANCE DOCUMENT allo-20230603_htm.xml XML 10870
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 23999170
SIC: 2836 Biological Products, (No Diagnostic Substances)